Amy E Newman

US Patent:

7605259, Oct 20, 2009

Filed:

Sep 15, 2003

Appl. No.:

10/527594

Inventors:

Amy Newman - Phoenix MD, US
Peter Grundt - Baltimore MD, US
Robert R. Luedtke - Fort Worth TX, US

Assignee:

University of North Texas Health Science Center at Fort Worth - Fort Worth TX

International Classification:

C07D 241/04
C07D 295/00

US Classification:

544358

Abstract:

A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.

US Patent:

8119642, Feb 21, 2012

Filed:

Sep 14, 2009

Appl. No.:

12/558983

Inventors:

Amy Newman - Phoenix MD, US
Peter Grundt - Baltimore MD, US
Robert R. Luedtke - Forth Worth TX, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
University of North Texas Health Science Center at Fort Worth - Fort Worth TX

International Classification:

A61K 31/4965
C07D 295/00

US Classification:

51425502, 544393

Abstract:

A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.

US Patent:

8383817, Feb 26, 2013

Filed:

Aug 24, 2006

Appl. No.:

12/063072

Inventors:

Amy Hauck Newman - Phoenix MD, US
Jonathan L. Katz - Columbia MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

C07D 451/00
C07D 451/02
C07D 43/42
C07D 451/06
A61K 31/439
A61K 31/46
A61K 31/44

US Classification:

546127, 546129, 514304

Abstract:

Disclosed are benztropine analogs having the formula (I) in which Ar is a C-Cmonocyclic aryl group or a C-Cbicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m=1 to 5; n=1 to 3; and Rto Rare as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e. g. , in treating mental disorders.

US Patent:

20080279775, Nov 13, 2008

Filed:

Jun 7, 2006

Appl. No.:

11/917036

Inventors:

Amy Hauck Newman - Phoenix MD, US
Peter Grundt - Duluth MN, US
Jonathan L. Katz - Columbia MD, US

Assignee:

GOVERNMENT OF THE UNITED STATED OF AMERICA, REPRESENTED BY THE SECRETARY, - Rockville MD

International Classification:

A61K 31/439
C07D 451/04
A61K 49/00
A61P 25/30

US Classification:

424 91, 546124, 514304

Abstract:

Disclosed are benztropinamine analogs having the formula I (I) in which E is NR, S, or CH; B is NR, O, or CH; m=1 to 5; n=1 to 3; Ar is a C-Cmonocyclic aryl group or a C-Cbicyclic aryl group or a heteroaryl group having 2 to 6 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, and any combination thereof; and bond “a” can be of α, β, or α/β configuration, wherein Rto Rare as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.

US Patent:

20100267737, Oct 21, 2010

Filed:

Jun 15, 2007

Appl. No.:

12/664668

Inventors:

Amy Hauck Newman - Phoenix MD, US
Peter Grundt - Baltimore MD, US
George C. Cyriac - Severna Park MD, US
Robert Luedtke - Forth Worth TX, US
Jianjing Cao - Baltimore MD, US

International Classification:

A61K 31/496
C07D 295/104
C07D 401/12
A61K 31/495
A61P 25/16
A61P 25/18
A61P 25/30
G01N 33/567

US Classification:

51425301, 544393, 544360, 51425503, 435 721

Abstract:

Dopamine Dreceptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved Dreceptor affinity and selectivity, as well as water solubility, is achieved. A series of linking-chain derivatives are disclosed wherein functionality such as OH or OAc groups have been introduced into the linking chain. In general, these modifications are well tolerated at Dreceptors and achieve high selectivity over Dand Dreceptors.

US Patent:

52583864, Nov 2, 1993

Filed:

Jun 5, 1991

Appl. No.:

7/715084

Inventors:

Amy H. Newman - Silver Spring MD
Frank C. Tortella - Columbia MD

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

A61K 31485

US Classification:

514289

Abstract:

It has been discovered that certain (+)-3-substituted-N-alkylmorphinans are ffective anticonvulsant and neuroprotective agents. Novel compounds having these biological properties are presented in a method of use for preventing, treating or controlling convulsions in mammals having a need for such treatment. The compounds do not lead to dependency, have low toxicity, and provide effective anticonvulsant or neuroprotective treatment with little or no behavioral detriment to the recipient. A number of pharmacological formulations and methods of administering compounds of the invention are suitable for anticonvulsive or neuroprotective treatments.

US Patent:

53310101, Jul 19, 1994

Filed:

Jun 5, 1991

Appl. No.:

7/715082

Inventors:

Amy H. Newman - Silver Spring MD
Silvia N. Calderon - Silver Spring MD
Frank C. Tortella - Columbia MD

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

A01N 3718
A01N 3302
C07C23300

US Classification:

514617

Abstract:

The compounds belong to the class of non-narcotic, non-opiate derivatives the 1-phenylalkanecarboxylic acid basic structure useful as anticonvulsant and neuroprotective agents. The compounds include novel derivatives as well as previously published species. Methods for controlling convulsions in a variety of pharmaceutical formulations and modalities are also provided.

US Patent:

56682859, Sep 16, 1997

Filed:

Mar 12, 1992

Appl. No.:

7/851672

Inventors:

Kenner C. Rice - Bethesda MD
Amy H. Newman - Silver Spring MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C07D48902

US Classification:

546 44

Abstract:

The invention involves a method of making key intermediates useful in the synthesis of many opiate narcotics and antagonists and agonists; and the non-opiate enantiomers thereof which have potent antitussive properties. The synthesis starts from either the natural or unnatural enantiomer of nordihydrocodeinone and produces 8, 14-dihydronorthebaine, the diketal of 7-bromonordihydrocodeinone, northebaine, norcodeinone diketal and 14-hydroxynorcodeinone intermediates without the necessity of leaving the N-nor structure. The syntheses have fewer steps than previous methods, and also have high yields.